Results 81 to 90 of about 1,156,734 (317)

Application of the Linear-Quadratic model to targeted radionuclide therapy

open access: yes, 2011
PhDThe principal aim of this work was to test the hypothesis that the Linear-Quadratic (LQ) model of cell survival, developed for external beam radiotherapy (EBRT), could be extended to targeted radionuclide therapy (TRT) in order to predict dose ...
Murray, Iain
core  

New Approaches to Targeted Therapy in Melanoma

open access: yes, 2023
It was just slightly more than a decade ago when metastatic melanoma carried a dismal prognosis with few, if any, effective therapies. Since then, the evolution of cancer immunotherapy has led to new and effective treatment approaches for melanoma ...
Jeffrey Sosman   +2 more
core   +1 more source

Diversity and complexity in neural organoids

open access: yesFEBS Letters, EarlyView.
Neural organoid research aims to expand genetic diversity on one side and increase tissue complexity on the other. Chimeroids integrate multiple donor genomes within single organoids. Self‐organising multi‐identity organoids, exogenous cell seeding, or enforced assembly of region‐specific organoids contribute to tissue complexity.
Ilaria Chiaradia, Madeline A. Lancaster
wiley   +1 more source

New strategy for monitoring targeted therapy: molecular imaging

open access: yes, 2013
Fei-Fei Teng, Xue Meng, Xin-Dong Sun, Jin-Ming YuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, People's Republic of ChinaAbstract: Targeted therapy is becoming an increasingly important ...
Teng FF, Sun XD, Yu JM, Meng X
core  

An Engineering Approach to Cancer Therapy Using Systemically Delivered siRNA [PDF]

open access: yes, 2007
The next generation of cancer therapeutics will specifically target processes responsible for the growth and survival of cancer cells. Among the most promising of these molecularly targeted therapeutics are small interfering RNAs (siRNAs). These siRNAs
Bartlett, Derek William
core   +1 more source

Pulmonary metastasectomy in the era of targeted therapy and immunotherapy

open access: yes, 2021
Metastatic melanoma is a fatal malignancy with a high mortality and morbidity. Since the early 1970s, available medical therapies were limited in improving survival. Surgery represented the best chance for a cure.
Bong, CY, Mark Smithers, B, Chua, TC
core   +1 more source

Organizing the interface—Plasma membrane architecture and receptor dynamics in virus‐cell interactions

open access: yesFEBS Letters, EarlyView.
Plasma membranes contain dynamic nanoscale domains that organize lipids and receptors. Because viruses operate at similar scales, this architecture shapes early infection steps, including attachment, receptor engagement, and entry. Using influenza A virus and HIV‐1 as examples, we highlight how receptor nanoclusters, multivalent glycan interactions ...
Jan Schlegel, Christian Sieben
wiley   +1 more source

Targeted delivery for treatments for restenosis and vein graft disease [PDF]

open access: yes, 2012
Surgery to restore blood flow in arteries blocked by atherosclerotic plaque is a common treatment in cardiovascular disease. Longtermcomplications of surgical treatment are vein graft disease and restenosis, a renarrowing of the blood vessel after ...
Thomas, Anita C
core   +1 more source

Epigenetic blind spots – the role of DNA methylation dynamics in stem cell‐based models of embryogenesis

open access: yesFEBS Letters, EarlyView.
Embryo‐like structures (stembryos) are an innovative tool, but they are hindered by experimental variability and limited developmental potential. DNA methylation is crucial for mammalian development, but its status in stembryo models is poorly characterized.
Sara Canil   +4 more
wiley   +1 more source

Targeted Therapy of Melanoma [PDF]

open access: yesJournal of Investigative Dermatology Symposium Proceedings, 2018
In recent years, the treatment of advanced melanoma has been revolutionized by the introduction of new innovative approaches, namely mutation-based targeted therapy and immune checkpoint blockade by CTLA4 and PD-1/PD-L1 inhibitors. The decade-long era of chemotherapy with very low response rates of 5-20% and short median survival rates of 6-9 months ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy